Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The presentation underscores the company’s efforts to generate real-world and clinical evidence for its flagship medicine, which received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025.
The announcement matters because TONMYA is the first new treatment for fibromyalgia in more than 15 years, according to the company. Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties, and patients have long faced limited therapeutic options. By sharing data at a major international pain congress, Tonix aims to bolster the clinical understanding of TONMYA’s impact on both symptoms and physical function, potentially supporting broader acceptance among clinicians and payers.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products including acute migraine therapies Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, suggesting that the drug’s franchise could extend beyond fibromyalgia if those studies succeed.
In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. The company is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These candidates remain investigational, and their efficacy and safety have not been established or approved for any indication.
For investors and industry observers, the IASP poster presentation represents a key opportunity to raise awareness of TONMYA among pain specialists and to reinforce the drug’s clinical profile ahead of potential broader adoption. The full press release can be viewed at https://ibn.fm/jFHh3, and ongoing updates about Tonix are available in the company’s newsroom at https://ibn.fm/TNXP.
The announcement was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform also offers corporate communications solutions designed to help companies reach investors and the public. Terms of use and disclaimers for TinyGems content are available at https://www.TinyGems.com/Disclaimer.
